CNTX
Context Therapeutics·NASDAQ
--
--(--)
--
--(--)
CNTX fundamentals
During Q4 2025, Context Therapeutics (CNTX) reported revenue of --, a YoY change of 0.00%. Net income was -13.03M, a YoY change of -289.65%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 499.97K -- | 651.60K -- | 651.06K -- | 769.54K -- | 840.32K +68.07% | 5.03M +671.27% | 1.57M +140.85% | 3.09M +301.78% | 3.44M +309.72% | 4.01M -20.25% | 4.05M +158.16% | 3.88M +25.56% | 6.67M +93.63% | 5.29M +32.05% | 6.18M +52.68% | 6.93M +78.58% | 3.82M -42.65% | 3.09M -41.64% | 18.70M +202.59% | 4.31M -37.83% | 5.53M +44.61% | 9.76M +215.95% | 10.61M -43.26% | 13.80M +220.26% | 39.70M -- |
Selling, General and Administrative Expenses | 288.21K -- | 285.36K -- | 182.39K -- | 174.71K -- | 401.58K +39.34% | 604.60K +111.87% | 828.46K +354.23% | 1.80M +929.32% | 2.09M +420.81% | 1.99M +229.24% | 1.97M +137.85% | 1.74M -3.38% | 2.13M +1.93% | 1.83M -7.99% | 1.70M -13.97% | 1.63M -6.11% | 1.85M -13.21% | 1.70M -6.96% | 1.88M +10.67% | 1.79M +9.85% | 2.07M +11.67% | 1.93M +13.14% | 1.89M +0.65% | 1.96M +9.60% | 7.85M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 930.67K -- | -- -- | -- -- | -- -- | 3.63M +290.36% | -- -- | -- -- | -- -- | 7.79M +114.43% | -- -- | -- -- | 1.70M -- | 1.63M -79.06% | 1.85M -- | 1.70M -- | 1.88M +10.67% | 1.79M +9.85% | 2.07M +11.67% | 1.93M +13.14% | 1.89M +0.65% | 1.96M +9.60% | 7.85M -- |
Research and Development Expenses | 211.76K -- | 366.23K -- | 468.67K -- | 594.84K -- | 438.74K +107.19% | 1.33M +264.00% | 739.60K +57.81% | 1.29M +117.48% | 1.35M +208.04% | 1.52M +13.81% | 2.08M +180.90% | 2.14M +65.80% | 4.53M +235.53% | 3.46M +128.11% | 4.49M +115.89% | 5.30M +147.19% | 1.97M -56.49% | 1.38M -59.99% | 16.83M +275.13% | 2.52M -52.50% | 3.46M +75.50% | 7.83M +465.56% | 8.72M -48.16% | 11.84M +370.17% | 31.86M -- |
Other Operating Expenses | -- -- | -- -- | -- -- | 0 -- | -- -- | 3.09M -- | -- -- | 0 -- | -- -- | 500.00K -83.81% | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -499.97K -- | -651.60K -- | -651.06K -- | -769.54K -- | -840.32K -68.07% | -5.03M -671.27% | -1.57M -140.85% | -3.09M -301.78% | -3.44M -309.72% | -4.01M +20.25% | -4.05M -158.16% | -3.88M -25.56% | -6.67M -93.63% | -5.29M -32.05% | -6.18M -52.68% | -6.93M -78.58% | -3.82M +42.65% | -3.09M +41.64% | -18.70M -202.59% | -4.31M +37.83% | -5.53M -44.61% | -9.76M -215.95% | -10.61M +43.26% | -13.80M -220.26% | -39.70M -- |
Non-Operating Income (Loss) | 1.33M -- | 8.13M -- | -225.18K -- | -15.21K -- | -51.73K -103.90% | -4.63K -100.06% | 125.27K +155.63% | 39 +100.26% | 4.63K +108.94% | 21.30K +560.14% | 193.78K +54.69% | 325.56K +834674.36% | 358.23K +7645.51% | 281.05K +1219.47% | 305.81K +57.81% | 163.32K -49.83% | 155.70K -56.54% | 834.04K +196.76% | 1.24M +305.98% | 967.51K +492.41% | 951.88K +511.34% | 930.85K +11.61% | 917.24K -26.12% | 779.04K -19.48% | 3.58M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | 9.88M -- | -- -- | -- -- | -- -- | 9.32K -99.91% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | 1.64M -- | 8.29M -- | -129.97K -- | -9.80M -- | 11.25K -99.31% | -4.32K -100.05% | 126.53K +197.36% | -9.59K +99.90% | -1.24K -111.01% | 4 +100.09% | 1.53K -98.79% | -2.30K +76.01% | 2.69K +316.95% | -12.23K -305775.00% | 15.37K +903.20% | -61.40K -2568.41% | 3.35K +24.74% | -6.11K +50.05% | -2.15K -114.00% | 3.48K +105.66% | -6.63K -297.88% | 27.08K +543.43% | 83.47K +3978.76% | 96.56K +2676.16% | 200.47K -- |
Net Interest Expense | 316.08K -- | 155.50K -- | 95.21K -- | 94.43K -- | 62.98K -80.07% | 309 -99.80% | 1.26K -98.68% | -315 -100.33% | -5.86K -109.31% | -21.30K -6991.91% | -192.25K -15345.44% | -327.86K -103983.49% | -355.54K -5963.13% | -293.27K -1277.13% | -290.44K -51.08% | -224.72K +31.46% | -152.35K +57.15% | -840.15K -186.47% | -1.24M -328.21% | -964.04K -329.00% | -958.52K -529.15% | -903.77K -7.57% | -833.77K +32.96% | -682.48K +29.21% | -3.38M -- |
Interest Expense | 316.08K -- | 155.50K -- | 95.21K -- | 94.43K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 5.86K -- | 21.30K -- | 192.25K -- | 327.86K -- | 355.54K +5963.13% | 293.27K +1277.13% | 290.44K +51.08% | 224.72K -31.46% | 152.35K -57.15% | 840.15K +186.47% | 1.24M +328.21% | 964.04K +329.00% | 958.52K +529.15% | 903.77K +7.57% | 833.77K -32.96% | 682.48K -29.21% | 3.38M -- |
Pretax Income From Continuing Operations | 826.48K -- | 7.48M -- | -876.24K -- | -784.75K -- | -892.05K -207.93% | -5.03M -167.26% | -1.44M -64.66% | -3.09M -293.99% | -3.44M -285.44% | -3.99M +20.75% | -3.85M -167.14% | -3.56M -15.04% | -6.31M -83.47% | -5.01M -25.71% | -5.87M -52.42% | -6.77M -90.34% | -3.67M +41.86% | -2.25M +55.01% | -17.46M -197.21% | -3.34M +50.62% | -4.58M -24.80% | -8.83M -291.55% | -9.69M +44.48% | -13.03M -289.65% | -36.12M -- |
Income Tax Expense | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | 826.48K -- | 7.48M -- | -876.24K -- | -784.75K -- | -892.05K -207.93% | -5.03M -167.26% | -1.44M -64.66% | -3.09M -293.99% | -3.44M -285.44% | -3.99M +20.75% | -3.85M -167.14% | -3.56M -15.04% | -6.31M -83.47% | -5.01M -25.71% | -5.87M -52.42% | -6.77M -90.34% | -3.67M +41.86% | -2.25M +55.01% | -17.46M -197.21% | -3.34M +50.62% | -4.58M -24.80% | -8.83M -291.55% | -9.69M +44.48% | -13.03M -289.65% | -36.12M -- |
Net Income Attributable to Owners of the Company | 826.48K -- | 7.48M -- | -876.24K -- | -784.75K -- | -892.05K -207.93% | -5.03M -167.26% | -1.44M -64.66% | -3.09M -293.99% | -3.44M -285.44% | -3.99M +20.75% | -3.85M -167.14% | -3.56M -15.04% | -6.31M -83.47% | -5.01M -25.71% | -5.87M -52.42% | -6.77M -90.34% | -3.67M +41.86% | -2.25M +55.01% | -17.46M -197.21% | -3.34M +50.62% | -4.58M -24.80% | -8.83M -291.55% | -9.69M +44.48% | -13.03M -289.65% | -36.12M -- |
Other Adjustments | -- -- | -- -- | -- -- | 5.57M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | 826.48K -- | 7.48M -- | -876.24K -- | -6.36M -- | -892.05K -207.93% | -5.03M -167.26% | -1.44M -64.66% | -3.09M +51.37% | -3.44M -285.44% | -3.99M +20.75% | -3.85M -167.14% | -3.56M -15.04% | -6.31M -83.47% | -5.01M -25.71% | -5.87M -52.42% | -6.77M -90.34% | -3.67M +41.86% | -2.25M +55.01% | -17.46M -197.21% | -3.34M +50.62% | -4.58M -24.80% | -8.83M -291.55% | -9.69M +44.48% | -13.03M -289.65% | -36.12M -- |
Other Comprehensive Income | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Basic EPS | -- -- | -- -- | -2.52 -- | -- -- | -2.55 -- | -14.18 -- | -4 -58.73% | -0.46 -- | -0.22 +91.37% | -0.25 +98.24% | -0.24 +94.00% | -0.22 +52.17% | -0.4 -81.82% | -0.31 -24.00% | -0.37 -54.17% | -0.42 -90.91% | -0.23 +42.50% | -0.04 +87.10% | -0.22 +40.54% | -0.04 +90.48% | -0.05 +78.26% | -0.09 -125.00% | -0.1 +54.55% | -0.14 -250.00% | -0.38 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.37 -- | -- -- | -0.23 -- | -0.04 -- | -0.22 +40.54% | -- -- | -0.05 +78.26% | -0.09 -125.00% | -0.1 +54.55% | -- -- | -- -- |
Diluted EPS | -- -- | -- -- | -2.52 -- | -- -- | -2.55 -- | -14.18 -- | -4 -58.73% | -- -- | -0.22 +91.37% | -0.25 +98.24% | -0.24 +94.00% | -- -- | -0.4 -81.82% | -0.31 -24.00% | -0.37 -54.17% | -- -- | -0.23 +42.50% | -0.04 +87.10% | -0.22 +40.54% | -- -- | -0.05 +78.26% | -0.09 -125.00% | -0.1 +54.55% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.37 -- | -- -- | -0.23 -- | -0.04 -- | -0.22 +40.54% | -- -- | -0.05 +78.26% | -0.09 -125.00% | -0.1 +54.55% | -- -- | -- -- |
You can ask Aime
What were the key takeaways from Context Therapeutics’s earnings call?What factors drove the changes in Context Therapeutics's revenue and profit?What is Context Therapeutics's gross profit margin?What guidance did Context Therapeutics's management provide for the next earnings period?What is the market's earnings forecast for Context Therapeutics next quarter?What is the revenue and EPS growth rate for Context Therapeutics year over year?Did Context Therapeutics beat or miss consensus estimates last quarter?What is Context Therapeutics's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
